BerandaABVX • EPA
add
Abivax SA
Tutup sebelumnya
€5,25
Rentang hari
€5,12 - €5,42
Rentang tahun
€4,51 - €15,42
Kapitalisasi pasar
345,55Â jt EUR
Volume Rata-Rata
66,56Â rb
Rasio P/E
-
Hasil dividen
-
Bursa utama
EPA
Berita pasar
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (EUR) | Des 2024info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 2,00Â jt | 72,23% |
Biaya operasional | 48,50Â jt | 4,95% |
Laba bersih | -47,30Â jt | 1,24% |
Margin laba bersih | -2,36Â rb | 42,65% |
Penghasilan per saham | — | — |
EBITDA | -46,03Â jt | -2,90% |
Tarif pajak efektif | — | — |
Neraca
Total aset
Total liabilitas
| (EUR) | Des 2024info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 144,36Â jt | -44,72% |
Total aset | 205,23Â jt | -37,25% |
Total liabilitas | 164,64Â jt | 25,63% |
Total ekuitas | 40,58 jt | — |
Saham yang beredar | 63,38 jt | — |
Harga terhadap nilai buku | 8,20 | — |
Tingkat pengembalian aset | -56,64% | — |
Tingkat pengembalian modal | -77,59% | — |
Arus Kas
Perubahan kas bersih
| (EUR) | Des 2024info | Perubahan Y/Y |
|---|---|---|
Laba bersih | -47,30Â jt | 1,24% |
Kas dari operasi | -34,45Â jt | 0,91% |
Kas dari investasi | 1,15Â jt | 136,10% |
Kas dari pembiayaan | -6,06Â jt | -105,54% |
Perubahan kas bersih | -39,05Â jt | -156,77% |
Arus kas bebas | -26,53Â jt | -4,57% |
Tentang
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has one program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, MA. Abivax’s R&D work is conducted at its research center based in Montpellier, France. Wikipedia
Didirikan
4 Des 2013
Situs
Karyawan
69
